Sosei Group Corporation has acquired a clinical-stage private UK-based biotechnology firm to share development of innovative medicines, according to a press release dated 22 February.
Heptares Therapeutics Limited will become a wholly owned subsidiary of the Japanese bio-pharmaceutical firm, while retaining its existing R&D operations in the UK.
It is hoped the tie-up will create a global biopharmaceutical group with access to pharmaceutical markets worldwide and regulatory expertise across the EU, Japan and the US.